Clearside Biomedical Book Value 2011-2026 | CLSD

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Clearside Biomedical

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-15.9 M	10.6 M	38 M	8.76 M	11.2 M	23.6 M	21.4 M	71.7 M	-36.7 M	-19.2 M	-10.7 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
71.7 M	-36.7 M	9.33 M

Quarterly Book Value Clearside Biomedical

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-54 M	-48.7 M	-45.9 M	-38.9 M	-34.8 M	-28.3 M	-	-15.9 M	-12.8 M	-4.97 M	2.7 M	10.6 M	18.5 M	25.2 M	31.7 M	38 M	17.8 M	19.3 M	17 M	8.76 M	8.76 M	8.76 M	8.76 M	11.2 M	11.2 M	11.2 M	11.2 M	23.6 M	23.6 M	23.6 M	23.6 M	21.4 M	21.4 M	21.4 M	21.4 M	71.7 M	71.7 M	71.7 M	71.7 M	10.7 M	10.7 M	10.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
71.7 M	-54 M	11.6 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	5.1 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	29 M	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	27.8 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	99.6 M	-	0.74 %	$ 768 M	Israel
Galera Therapeutics GRTX	6.55 M	-	-32.59 %	$ 7.61 M	USA
Esperion Therapeutics ESPR	-302 M	$ 3.13	-	$ 651 M	USA
Eton Pharmaceuticals ETON	26.2 M	$ 34.45	4.74 %	$ 927 M	USA
Midatech Pharma plc MTP	11.4 M	-	-18.52 %	$ 27.3 M	Britain
Forte Biosciences FBRX	61 M	$ 20.31	1.2 %	$ 263 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Checkmate Pharmaceuticals CMPI	69.5 M	-	-	$ 231 M	USA
Grifols, S.A. GRFS	8.61 B	$ 8.19	4.46 %	$ 5.57 B	Spain
Celyad Oncology SA CYAD	19.7 M	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	142 M	-	-7.31 %	$ 87 M	USA
Arcturus Therapeutics Holdings ARCT	214 M	$ 6.82	1.94 %	$ 187 M	Israel
Generation Bio Co. GBIO	86.2 M	-	-	$ 344 M	USA
IMV IMV	-6.6 M	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
BioNTech SE BNTX	19.2 B	$ 90.36	2.93 %	$ 21.8 B	Germany
Autolus Therapeutics plc AUTL	178 M	$ 1.62	-0.61 %	$ 431 M	Britain
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Cyclacel Pharmaceuticals CYCCP	6.84 M	-	-4.36 %	$ 27 M	USA
Compugen Ltd. CGEN	157 M	$ 2.71	-0.92 %	$ 253 M	Israel
Anika Therapeutics ANIK	190 M	$ 15.14	2.16 %	$ 217 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	3.84 M	-	5.93 %	$ 314 M	Canada
Incyte Corporation INCY	5.17 B	$ 97.08	1.55 %	$ 19 B	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 3.39	4.17 %	$ 5.58 M	Israel
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Coherus BioSciences CHRS	61 M	$ 1.51	2.03 %	$ 177 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	78.8 M	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	189 M	$ 20.47	4.97 %	$ 2.6 B	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA